Mutant K-ras Regulates Cathepsin B Localization on the Surface of Human Colorectal Carcinoma Cells

Neoplasia

Volumn 5, Issue 6, 2003, Pages 507-519

  Cavallo Medved, Dora ^a   Dosescu, Julie ^a   Linebaugh, Bruce E ^a   Sameni, Mansoureh ^a   Rudy, Debbie ^a   Sloane, Bonnie F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Caveolae; Cysteine proteases; K ras; Membrane associated proteases

Indexed keywords

ANNEXIN; CATHEPSIN B; CAVEOLIN 1; K RAS PROTEIN; PROTEIN; PROTEIN P11; TETRAMER; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ALLELISM; ARTICLE; BINDING SITE; CELL FRACTIONATION; CELL INTERACTION; CELL SURFACE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TUMOR CELL LINE;

EID: 0347683401     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80035-0     Document Type: Article

References (75)

1. Liotta LA, Rao CN, and Barsky SH (1983). Tumor invasion and the extracellular matrix. Lab Invest 49, 636-49.
2. McCawley LJ, and Matrisian LM (2001). Tumor progression: defining the soil round the tumor seed. Curr Biol 11, R25-R37.
3. Mignatti P, Robbins E, and Rifkin DB (1986). Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47, 487-98.
4. Koblinski JE, Ahram M, and Sloane BF (2000). Unraveling the role of proteases in cancer. Clin Chim Acta 291, 113-35.
5. Nishimura Y, Kawabata T, and Kato K (1988). Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 261, 64-71.
6. Mort JS, and Buttle DJ (1997). Cathepsin B. Int J Biochem Cell Biol 29, 715-20.
7. Buck MR, Karustis DG, Day NA, Honn KV, and Sloane BF (1992). Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282, 273-78.
8. Rozhin J, Robinson D, Stevens MA, Lah TT, Honn KV, Ryan RE, and Sloane BF (1987). Properties of a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic melanoma variants. Cancer Res 47, 6620-628.
9. Rozhin J, Sameni M, Ziegler G, and Sloane BF (1994). Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54, 6517-525.
10. Linebaugh BE, Sameni M, Day NA, Sloane BF, and Keppler D (1999). Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem 264, 100-109.
11. Brix K, Linke M, Tepel C, and Herzog V (2001). Cysteine proteinases mediate extracellular prohormone processing in the thyroid. Biol Chem 382, 717-25.
12. Sameni M, Moin K, and Sloane BF (2000). Imaging proteolysis by living human breast cancer cells. Neoplasia 2, 496-504.
13. Sameni M, Dosescu J, Moin K, and Sloane BF (2003). Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. Mol Imaging 2, 1-17.
14. Sameni M, Dosescu J, and Sloane BF (2001). Imaging proteolysis by living human glioma cells. Biol Chem 382, 785-88.
15. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, and Terao T (1993). Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 84, 633-40.
16. Ikeda Y, Ikata T, Mishiro T, Nakano S, Ikebe M, and Yasuoka S (2000). Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J Med Invest 47, 61-75.
17. Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners Jr, JJ 2002. Phorbol ester activation of a proteolytic cascade capable of activating latent TGF-β: a process initiated by the exocytosis of cathepsin B. J Biol Chem 277, 14829-837.
18. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, Piek E, and Bottinger EP (2001). Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci USA 98, 6686-691.
19. Yan Z, Kim GY, Deng X, and Friedman E (2002). Transforming growth factor beta 1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1. J Biol Chem 277, 9870-879.
20. Campo E, Munoz J, Miquel R, Palacin A, Cardesa A, Sloane BF, and Emmert-Buck MR (1994). Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 145, 301-309.
21. Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, Jonker A, Van Driel BE, Lyon H, Hansen U, Kohler A, and Van Noorden CJ (2000). Comparative localization of cathepsin B protein and activity in colorectal cancer. J Histochem Cytochem 48, 1421-430.
22. Fearon E, and Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-67.
23. Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, and Ziegler G (1994). Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci 107, 373-84.
24. Marten K, Bremer C, Khazaie K, Sameni M, Sloane BF, Tung CH, and Weissleder R (2002). Detection of dysplastic intestinal adenomas using enzyme sensing molecular beacons in mice. Gastroenterology 122, 406-14.
25. Dove WF, Gould KA, Luongo C, Moser AR, and Shoemaker AR (1995). Emergent issues in the genetics of intestinal neoplasia. Cancer Surv 25, 335-55.
26. Shirasawa S, Furuse M, Yokoyama N, and Sasazuki T (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85-88.
27. White MA, and Anderson RG (2001). Which Ras rides the raft? Nat Cell Biol 3, E172.
28. Stahl A, and Mueller BM (1995). The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 129, 335-44.
29. Annabi B, Lachambre M, Bousquet-Gagnon N, Page M, Gingras D, and Beliveau R (2001). Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 353, 547-53.
30. Puyraimond A, Fridman R, Lemesle M, Arbeille B, and Menashi S (2001). MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 262, 28-36.
31. Sargiacomo M, Sudol M, Tang Z, and Lisanti MP (1993). Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 122, 789-807.
32. 2+. Biochem Biophys Acta 1223, 375-82.
33. Kim J, and Hajjar KA (2002). Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 7, 341-48.
34. Mai J, Finley Jr, RL, Waisman DM, and Sloane BF 2000. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem 275, 12806-812.
35. Allgayer H, Wang H, Shirasawa S, Sasazuki T, and Boyd D (1999). Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulated urokinase receptor expression and plasminogen dependent proteolysis, Br J Cancer 80, 1884-891.
36. Moin K, Day NA, Sameni M, Hasnain S, Hirama T, and Sloane BF (1992). Human tumour cathepsin B. Comparison with normal liver cathepsin B. Biochem J 285, 427-34.
37. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, and Lisanti MP (1996). Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271, 9690-697.
38. Smart EJ, Ying Y, Mineo C, and Anderson RG (1995). A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci USA 92, 10104-108.
39. Willingham MC (1990). Immunocytochemical methods: useful and informative tools for screening hybridomas and evaluating antigen expression. Focus 12, 62-67.
40. Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, Towatari T, Nikawa T, and Katuruma N (1991). Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett 280, 307-10.
41. Waisman D (1995). Annexin II tetramer: structure and function. Mol Cell Biochem 149 (150), 301-22.
42. Choi KS, Fogg DK, Yoon CS, and Waisman DM (2003). p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J 17, 235-46.
43. Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, Zackson S, Toba M, Shinomiya A, and Waisman DM (1998). The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 273, 4790-799.
44. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka YH, Tu YH, Cook RF, and Sargiacomo M (1994). Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126, 111-26.
45. Scherer PE, Tang Z, Chun M, Sargiacomo M, Lodish H, and Lisanti MP (1995). Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 270, 16395-401.
46. Wei Y, Yang X, Liu Q, Wilkins JA, and Chapman HA (1999). A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 144, 1285-294.
47. Schwab W, Gavlik JM, Beichler T, Funk RH, Albrecht S, Magdolen V, Luther T, Kasper M, and Shakibael M (2001). Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin. Histochem Cell Biol 115, 317-23.
48. Cavallo-Medved D, and Sloane BF (2003). Cell surface cathepsin B: understanding its functional significance. In Zucker S, Chen W-T (Eds.), Cell Surface Proteases, pp. 313-41 Elsevier, USA.
49. Bos JL, Verlaan-de Vries M, Marshall CJ, Veeneman GH, van Boom AJ, and van der Eb AJ (1986). A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res 14, 1209-217.
50. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, and Vogelstein B (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-97.
51. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa T, Sasazuki T, and Kerbel RS (1998). Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95, 3609-614.
52. Premzl A, Zavasnik-Bergant V, Turk V, and Kos J (2003). Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 283, 206-14.
53. Donatien PD, Diment SL, Boissy RE, and Orlow SJ (1996). Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v-ras-Ha oncogene. Int J Cancer 66, 557-63.
54. Pascoe D, and Oursler MJ (2001). The Src signaling pathway regulates osteoclast lysosomal enzyme secretion and is rapidly modulated by estrogen. J Bone Miner Res 16, 1028-1036.
55. Yan Z, Deng X, Chen M, Xu Y, Ahram M, Sloane BF, and Friedman E (1997). Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem 272, 27902-907.
56. Kim K, Cai J, Shuja S, Kuo T, and Murnane MJ (1998). Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas. Int J Cancer 9, 324-33.
57. Yeatman TJ, Updyke TV, Kaetzel MA, Dedman JR, and Nicolson GL (1993). Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin Exp Metastasis 11, 37-44.
58. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, and Lisanti MP (1997). Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth, J Biol Chem 272, 16374-381.
59. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, and Conti CJ (1994). Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 54, 6370-373.
60. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJ, and Pemberton P (1994). RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb Symp Quant Biol 59, 537-46.
61. Koleske AJ, Baltimore D, and Lisanti MP (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92, 1381-385.
62. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, and Thompson TC (1998). Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4, 1873-880.
63. Yang G, Truong LD, Wheeler TM, and Thompson TC (1999). Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59, 5719-723.
64. Raijayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, and Mellon JK (2001). Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58, 811-14.
65. Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne G, Ben-Baruch G, Berner A, and Reich R (2001). Caveolin-1 expression in advanced-stage ovarian carcinoma-a clinicopathologic study. Gynecol Oncol 81, 166-71.
66. Lavie Y, Fiucci G, and Liscovitch M (1998). Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. Biol Chem 273, 32380-383.
67. Bender FC, Reymond MA, Bron C, and Quest AF (2000). Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60, 5870-878.
68. Yang C-PH, Galbiati F, Volonte D, Horwitz SB, and Lisanti MP (1998). Upregulation of and caveolin-1 caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 439, 368-72.
69. Fine SW, Lisanti MP, Galbiati F, and Li M (2001). Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 115, 719-24.
70. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, and Thompson TC (2001). Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61, 3882-885.
71. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer T, Okamoto T, and Lisanti MP (1999). Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19, 7289-304.
72. Mai J, Waisman DM, and Sloane BF (2000). Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 36072, 1-16.
73. Hajjar KA, and Hamel NM (1990). Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 265, 2908-916.
74. Kassam G, Le BH, Choi KS, Kang HM, Fitzpatrick SL, Louie P, and Waisman DM (1998). Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Biochemistry 37, 16958-966.
75. Falcone DJ, Borth W, Khan KM, and Hajjar KA (2001). Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Blood 97, 777-84.